Relay Therapeutics (RLAY) CEO Sanjiv Patel Sells 48,199 Shares

What Happened

• Sanjiv Patel, President & CEO and director of Relay Therapeutics, sold 48,199 shares on 2026-09-08 in a sale that generated approximately $912,889. The filing reports a weighted average sale price of $18.94 per share; individual trades executed between $18.33 and $19.25. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Patel on October 30, 2025. This was a sale (routine disposition), not a purchase.

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-09 (timely).
• Shares sold: 48,199; Weighted average price: $18.94; Total proceeds: ~$912,889.
• Price range across multiple trades: $18.33 to $19.25 (reporting person offers to provide per-trade breakdown on request).
• Trade executed under a Rule 10b5-1 plan (adopted 10/30/2025).
• Footnote indicates the shares were held in irrevocable trusts for family members with an independent trustee; Mr. Patel disclaims beneficial ownership of those trust shares.
• Shares owned after the transaction are not specified in the excerpt provided.

Context

• A 10b5-1 trading plan means the sale was likely pre-scheduled and should not be taken on its own as an indicator of the CEO’s current view of the company. The trust/independent trustee footnote suggests the reported holdings and sale relate to family trusts rather than direct beneficial ownership by the CEO.